US FDA’s Dose Optimization Postmarketing Requirements and Commitments of Oncology Approvals and the Impact on Product Labels from 2010 to 2022: An Emerging Landscape from Traditional to Novel Therapies

• Published in: Therapeutic innovation & regulatory science 2024-03, Vol.58 (2), p.380-386
• Main Authors: Gendy, Joseph M., Nomura, Naomi, Stuart, Jeffrey N., Blumenthal, Gideon
• Format: Article
• Language: English
• Subjects: Antibodies; Descriptive labeling; Dosage; Drug Approval - methods; Drug dosages; Drug Safety and Pharmacovigilance; Kinases; Labeling; Labels; Medicine; Oncology; Optimization; Original Research; Pharmaceutical Preparations; Pharmacotherapy; Pharmacy; Product Surveillance, Postmarketing; Uncertainty; United States; United States Food and Drug Administration
• ISSN: 2168-4790; 2168-4804
• DOI: 10.1007/s43441-023-00606-1

Background Dose optimization is a focal point of many US Food and Drug Administration (FDA) drug approvals. We sought to understand the impact of the FDA’s Postmarketing Commitments/Postmarketing Requirements (PMCs/PMRs) on dose optimization and prescriber labeling for oncology drugs. Methods Publicly available information was aggregated for all FDA oncology drug approvals between January 1, 2010, and December 31, 2022. Study completion dates were compared to product labeling before and after PMC/PMR fulfillment dates to evaluate labeling changes associated with dose-related PMCs/PMRs. Data were analyzed individually (2010–2015 and 2016–2022) due to differences in available information. Results From 2010 to 2015, 14 of 42 (33.3%) new molecular entities (NMEs) had dose-related PMCs/PMRs, with 6 of 14 (42.9%) resulting in a relevant label change. From 2016 to 2022, of the 314 new or supplemental applications approved, 21 had dose-related PMCs/PMRs (6.7%), which trended upward over time; 71.4% of dose-related PMCs/PMRs were NMEs. Kinase inhibitors (KIs) and antibody/peptide drug conjugates (ADCs/PDCs) were the most affected drug classes. Ten of the 21 approvals with dose-related PMCs/PMRs fulfilled their dosing PMCs/PMRs, and 3 of the 10 (30%) had relevant label changes. Conclusion Most dose-related PMRs/PMCs were issued for NMEs. Of these, KIs and ADCs/PDCs were highly represented, reflecting their novelty and greater uncertainty around their safety profile. PMC/PMR issuance broadly increased over time. With the implementation of the FDA’s Project Optimus in 2021, it remains to be seen whether fewer dose-related PMCs/PMRs emerge in future due to enhanced dose optimization in the premarketing setting.